BioSpace News Archive

FH Ortho Inc, a well-established innovative orthopedic medical device company, is pleased to announce the FDA clearance of Telegraph Evolution, a next generation humeral nailing system for use in proximal and/or mid-shaft humeral fractures. Chris Valois, General Manager of FH Ortho Inc said, “We are seeing a trend in the US towards humeral fracture nails and away from plating due to advancements in instrumentation and perceived improved patient outc

TORONTO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (the “ Company ” or “ CB2 ”) (CSE:CBII OTCQB:CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce it will be participating in the Gravitas Technology and Diversified Investor Day taking place Thursday, October 15 th , 2020 virtually. CB2’s Chief Executive Officer, Pradyum Sekar, is scheduled to present on Thursday, October 15 th at 3:00 PM EST. Mr. Sekar will also be fielding investor qu

- Novellus’s iMSCs are derived from a single donor using its patented mRNA-based, footprint-free cell reprogramming technology - iMSCs overcome the significant challenges of limited supply and low potency associated with donor-derived MSCs [13-October-2020] CAMBRIDGE, Mass. , Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics (“Novellus”), an engineered cel

Kane Biotech Inc. announced that Kevin Cole will assume the role of President and CEO of STEM Animal Health Inc., a subsidiary created from the recently formed joint venture with UK-based international veterinary products company, Animalcare Group PLC .

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU). CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of ce

PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate PC14586,

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are advancing VXA-CoV2-

Parata Systems, a leading provider of pharmacy automation, including vial-filling, adherence packaging, and workflow and patient experience solutions, announces the launch of a new, dual adherence packager for both blister and pouch

Study Shows PixCell’s HemoScreen™ May Be Used to Monitor Pathological Blood Samples, Improving Treatment Process for Hematological Patients

Almirall, S.A. (ALM) announced today that it has signed an agreement with the French Authorities to make the biologic treatment ILUMETRI® (tildrakizumab), a high-affinity IL-23p19 monoclonal antibody, available in France for the treatment of adult patients with severe plaque psoriasis who are candidates for biological systemic therapy.